Thai Drug Firms Face Uncertain Year In Sluggish Market
This article was originally published in PharmAsia News
Executive Summary
Thailand's pharmaceutical industry is bracing for a possible slowdown in the growth of the market that grew by 18 percent last year. President Teera Chajnarodom, president of the Pharmaceutical Research and Manufacturers Association, said sales already are sluggish in the current quarter, primarily because hospital expenditures on medicines have slowed. He says he cannot predict the current year, but said the country has a new government and has not yet implemented an economic stimulus package. (Click here for more
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.